Warning: This product has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device.

Addressing The Unmet Need of Ocular Pain

EyeCool Therapeutics is committed to delivering fast, lasting relief for patients suffering from Chronic Ocular Surface Pain (COSP)

~4.1M

~4.1M

The esimated number of U.S. adults suffering from Chronic Ocular Pain, a condition with no FDA-approved therapies

47%

47%

The percentage of patients with Chronic Ocular Pain that report having struggled with depression

61%

61%

The percentage of patients with Chronic Ocular Pain that report being less productive at work

5th

5th

Population-level ranking of the “top five” reasons for eye care visits based on prevalence of diagnostic claims

Latest News

EyeCool Therapeutics Announces New ETX-4143 Data to Be Presented at ARVO 2026